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Additive triple DMARD combination therapy
of a low dose of sulfhydryl compounds,
sulfasalazine and methotrexate in the treatment
of rheumatoid arthritis: a clinical trial.∗
Koji Nishiya, Naoko Hisakawa, Kiyoshi Tahara, Akinori Matsumori, Hiroyuki
Ito, Kozo Hashimoto, Ko Nakatani, and Kazuhiro Takatori
Abstract
To evaluate the efficacy and safety of additive triple disease modifying anti-rheumatic drug
(DMARD) combination therapy of a low dose of sulfhydryl compounds inverted question markD-
penicillamine, bucillamine or tiopronin inverted question mark, sulfasalazine (SSZ) and methotrex-
ate (MTX) as a treatment for rheumatoid arthritis (RA) patients, we studied a total of 33 Japanese
RA patients (6 males, 27 females). At 1 or 2 months after simultaneous administration of the 3
above-mentioned DMARDs was begun, significant improvements were seen in markers of joint
inflammation, i.e., erythrocyte sedimentation rate and C-reactive protein in sera. At 6 months,
clinical improvement judged by the physicians’ overall assessment of joint symptoms and labora-
tory data was observed in 29 (88%) of the 33 RA patients. No marked effect was observed in the
other 4 (12%) patients, however. We observed no significant adverse reaction to this therapy. This
suggests that additive triple DMARD combination therapy of a low dose of sulfhydryl compounds,
SSZ and MTX could be a useful drug therapy for the treatment of RA patients, even those who are
refractory.
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